Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13530879 | 0.86 | ROCK2 (0.53) | ROCK2ROCK1KMT2AMEN1MAPK1 | |
| SCHEMBL13530677 | 0.86 | POLB (0.48) | ROCK2ROCK1MAPK1RAB9AMAOB | |
| SCHEMBL1224382 | 0.81 | KDM4E (0.50) | ROCK1KMT2AMEN1PKMHPGD | |
| SCHEMBL13529914 | 0.80 | KMT2A (0.43) | ROCK2ROCK1KMT2AMEN1MAPK1 | |
| SCHEMBL13530698 | 0.79 | EPHX2 (0.57) | ROCK2ROCK1KMT2AMEN1MAPK1 | |
| SCHEMBL14724901 | 0.79 | KMT2A (0.44) | ROCK2ROCK1KMT2AMEN1MAPK1 | |
| SCHEMBL13530116 | 0.79 | MAPK1 (0.44) | ROCK2ROCK1KMT2AMEN1MAPK1 | |
| SCHEMBL13529782 | 0.77 | KMT2A (0.53) | ROCK2ROCK1KMT2AMEN1MAPK1 | |
| SCHEMBL13529972 | 0.77 | KMT2A (0.43) | ROCK2ROCK1KMT2AMEN1MAPK1 | |
| SCHEMBL1270948 | 0.77 | SMN1; SMN2 (0.50) | ROCK2ROCK1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9204653-B2 | 5-fluoro pyrimidine derivatives | DOW AGROSCIENCES LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9204653-B2 | 5-fluoro pyrimidine derivatives | DOW AGROSCIENCES LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DPYD, DPM1, DDX5 | ROCK2 3139/4885ROCK1 4041/4885KMT2A 3037/4885 |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DPYD, DPM1, DDX5 | ROCK2 3139/4885ROCK1 4041/4885KMT2A 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.